Key Points
- CFO Kyle Piskel sold 162,820 shares on November 28 at an average of $19.50 for about $3.17 million, trimming his stake by 42.91 to 216,637 shares valued at roughly $4.22 million.
- Adaptive reported Q3 revenue of $93.97 million, up 102.4% year‑over‑year and beating EPS estimates (loss of $0.15 vs. $0.16 expected), though the company remains unprofitable with negative net margin and return on equity.
- The stock trades in a 52‑week range of $5.80–$20.76 with a $2.85 billion market cap, and analysts hold an average rating of "Moderate Buy" with a $17.11 consensus target.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) CFO Kyle Piskel sold 162,820 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $19.50, for a total transaction of $3,174,990.00. Following the transaction, the chief financial officer directly owned 216,637 shares in the company, valued at $4,224,421.50. This trade represents a 42.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kyle Piskel also recently made the following trade(s):
- On Monday, November 17th, Kyle Piskel sold 238 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.05, for a total value of $3,343.90.
Adaptive Biotechnologies Stock Performance
ADPT stock opened at $18.69 on Wednesday. The stock's 50 day simple moving average is $16.16 and its 200 day simple moving average is $13.09. The company has a market cap of $2.85 billion, a P/E ratio of -34.61 and a beta of 2.20. Adaptive Biotechnologies Corporation has a fifty-two week low of $5.80 and a fifty-two week high of $20.76.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million during the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the previous year, the company posted ($0.22) earnings per share. The company's quarterly revenue was up 102.4% on a year-over-year basis. Equities analysts predict that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.
Analyst Ratings Changes
ADPT has been the topic of several research reports. Guggenheim started coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 30th. They set a "buy" rating and a $20.00 price objective on the stock. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $13.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, August 6th. Wall Street Zen raised shares of Adaptive Biotechnologies from a "hold" rating to a "buy" rating in a research report on Saturday, November 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Wednesday, October 8th. Finally, BTIG Research increased their price objective on Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, November 6th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Adaptive Biotechnologies currently has an average rating of "Moderate Buy" and an average target price of $17.11.
Get Our Latest Research Report on Adaptive Biotechnologies
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Adaptive Biotechnologies by 3.1% in the 3rd quarter. Brighton Jones LLC now owns 23,301 shares of the company's stock worth $349,000 after purchasing an additional 700 shares in the last quarter. Bouvel Investment Partners LLC boosted its stake in shares of Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company's stock worth $641,000 after buying an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Adaptive Biotechnologies by 3.1% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company's stock worth $355,000 after buying an additional 910 shares during the last quarter. California State Teachers Retirement System grew its holdings in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company's stock valued at $1,145,000 after acquiring an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in shares of Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company's stock valued at $184,000 after acquiring an additional 1,119 shares during the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
